ELMSFORD, N.Y., April 16, 2013 /PRNewswire/ -- BioScrip,
Inc. (NASDAQ: BIOS) (the "Company" or "BioScrip") today announced
it has commenced an underwritten public offering of its common
stock. Both the Company and certain selling stockholders will offer
shares of the Company's common stock as part of the public
offering. BioScrip will not receive any proceeds from the
sale of shares of common stock by the selling
stockholders.
(Logo:
http://photos.prnewswire.com/prnh/20130117/NY44138LOGO )
Jefferies LLC, Morgan Stanley & Co. LLC and SunTrust
Robinson Humphrey, Inc. are acting as joint book-running managers.
Dougherty & Company and Noble Financial Capital Markets are
acting as co-managers. The Company and the selling stockholders
expect to grant the underwriters a 30-day option to purchase up to
an additional 15% of the shares of common stock offered in the
public offering. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the final size or terms of the
offering.
The securities described above are being offered by BioScrip and
the selling stockholders pursuant to a registration statement
previously filed and declared effective by the Securities and
Exchange Commission. This press release does not constitute an
offer to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. Copies of
the prospectus supplement and accompanying base prospectus relating
to this offering may be obtained from: Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th
Floor, New York, New York, 10022,
Telephone: 877-547-6340, Email:
Prospectus_Department@Jefferies.com; Morgan Stanley & Co. LLC,
180 Varick Street, 2nd Floor, New York,
New York 10014, Attention: Prospectus Department, Telephone:
866-718-1649, Email: prospectus@morganstanley.com; or SunTrust
Robinson Humphrey, Attention: Prospectus Department, 3333 Peachtree
Rd. NE, Atlanta, Georgia 30326,
Telephone: 404-926-5744, Email: STRH.Prospectus@SunTrust.com.
About BioScrip
BioScrip, Inc. provides comprehensive infusion and home care
solutions. By partnering with patients, physicians, healthcare
payors, government agencies and pharmaceutical manufacturers we are
able to provide access to infusible medications and management
solutions. Our goal is to optimize outcomes for chronic and other
complex healthcare conditions and enhance the quality of patient
life. BioScrip brings clinical competence in providing high-touch,
comprehensive infusion and nursing services to patients in the most
convenient ways possible. Through our customer services and
treatments we aim to ensure the best possible therapy outcome.
Forward Looking Statements
This press release includes statements that may constitute
"forward-looking statements," that involve substantial risks and
uncertainties. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. You can identify these statements by the fact
that they do not relate strictly to historical or current facts.
In some cases, forward-looking statements can be identified
by words such as "may," "should," "could," "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe,"
"predict," "potential," "continue" or comparable
terms. These forward-looking statements include, among others,
statements about the Company's expectations with respect to the
proposed offering, including its intention to offer and sell shares
and its intended use of proceeds from the offering. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, which may cause actual results to
be materially different from any results expressed or implied by
such forward-looking statements. For example, there are risks
associated with market conditions, the underwriters fulfilling
their obligations to purchase the shares in the offering and the
Company's ability to satisfy certain conditions precedent to the
closing of the offering; as well as the risks described in the
Company's periodic filings with the Securities and Exchange
Commission, including, but not limited to, the Company's annual
report on Form 10-K for the year ended December
31, 2012. The Company does not undertake any duty
to update these forward-looking statements after the date hereof,
even though the Company's situation may change in the
future. All of the forward-looking statements herein are
qualified by these cautionary statements.
SOURCE BioScrip, Inc.